Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04487691 · ClinicalTrials.gov registry record · NA
Nebulized PL for Post-COVID-19 Syndrome
A NA study, sponsored by Regenexx.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT04487691 is a NA study that was terminated before completion, run by Regenexx. The registered enrollment target is 1 participants.
The verdict
NCT04487691, a NA study, was terminated before completion, sponsored by Regenexx.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
To evaluate and compare nebulized platelet lysate to placebo control of saline administered via handheld nebulizer 1x daily for eight weeks to determine effect on lung function in patients with post-COVID-19 ARDS syndrome.
Interventions
- BIOLOGICAL Nebulized Platelet Lysate
- OTHER Nebulized Sterile Saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-12-08 |
| Est. Completion | 2021-06-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04487691
The ClinicalTrials.gov registry entry for NCT04487691 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regenexx, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nebulized Platelet Lysate is the first listed.
NCT04487691 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04487691 about?
NCT04487691 is a clinical study titled "Nebulized PL for Post-COVID-19 Syndrome". To evaluate and compare nebulized platelet lysate to placebo control of saline administered via handheld nebulizer 1x daily for eight weeks to determine effect on lung function in patients with post-COVID-19 ARDS syndrome.
What is the current status of trial NCT04487691?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2020-12-08. Estimated completion is 2021-06-15.
What interventions are being tested in trial NCT04487691?
The interventions under investigation include: Nebulized Platelet Lysate (BIOLOGICAL), Nebulized Sterile Saline (OTHER).
Who is sponsoring clinical trial NCT04487691?
This trial is sponsored by Regenexx, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.